← Leaderboards
Sunjay Kaushal
Lurie Children'S Hospital Of Chicago
$9,064,158
Attributed
$13,124,112
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2009–24$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$13,124,112 · 7
By mechanism
R01$10,234,205 · 4
UH3$1,586,672 · 1
UG3$657,935 · 1
K08$645,300 · 1
Top collaborators
- Peixin Yang9 shared
- Joshua M Hare3 shared
- Stuart Berger1 shared
- Michael L. Terrin1 shared
Most similar at Lurie Children'S Hospital Of Chicago
Same institution · by research overlap
- Jami L Josefson$5,049,689
- Daniel T. Robinson$2,359,258
- Stuart Berger$585,228
- Kiona Allen$518,160
- Monica Bianco$191,245
Others in their field
Top investigators on “Stem Cells”
- Mary M Horowitz · Medical College Of Wisconsin$220,248,453
- David Heimbrook · Leidos Biomedical Research, Inc.$161,931,307
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$73,044,559
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$70,591,644
- Michelle M Le Beau · University Of Chicago$70,506,423
Research focus
Stem CellsCardiacIn VitroCellsHeartCongenital Heart DefectsApoptosisRegenerativeMyocardialTransplantationCardiac MyocytesMyocardiumDesignRepairedFunctional DisorderAdultIn VivoMyocardial InfarctionBaseAffectCell TherapyBiologyClinical TrialsHeart Failure
Grant awards (27)
1/2 Allogeneic Human Mesenchymal Stem Cell (MSC) Injection in Patients with Hypoplastic Left Heart Syndrome: A Phase IIb Clinical Trial$408,351
UH3 · FY2024 · HL
Hyperglycemia of Maternal Diabetes Induces Cardiac Isl1 Positive Progenitor Dysfunction Leading to Heart Defects$615,074
R01 · FY2023 · HL
Characterization of the Cardiac Progenitor Cell Exosomes for Optimal Therapeutics$686,112
R01 · FY2022 · HL · contact PI
Hyperglycemia of Maternal Diabetes Induces Cardiac Isl1 Positive Progenitor Dysfunction Leading to Heart Defects$615,074
R01 · FY2022 · HL
1/2 Allogeneic Human Mesenchymal Stem Cell (MSC) Injection in Patients with Hypoplastic Left Heart Syndrome: A Phase IIb Clinical Trial$1,178,321
UH3 · FY2021 · HL · contact PI
Characterization of the Cardiac Progenitor Cell Exosomes for Optimal Therapeutics$729,215
R01 · FY2021 · HL · contact PI
Mechanism of transplanted neonatal cardiac progenitor cells to repair ischemic myocardium$643,173
R01 · FY2021 · HL · contact PI
Hyperglycemia of Maternal Diabetes Induces Cardiac Isl1 Positive Progenitor Dysfunction Leading to Heart Defects$615,074
R01 · FY2021 · HL
Characterization of the Cardiac Progenitor Cell Exosomes for Optimal Therapeutics$742,840
R01 · FY2020 · HL · contact PI
1/2 Allogeneic Human Mesenchymal Stem Cell (MSC) Injection in Patients with Hypoplastic Left Heart Syndrome: A Phase IIb Clinical Trial$657,935
UG3 · FY2020 · HL · contact PI
Hyperglycemia of Maternal Diabetes Induces Cardiac Isl1 Positive Progenitor Dysfunction Leading to Heart Defects$615,074
R01 · FY2020 · HL
The Role of C-Kit Positive Cardiac Progenitors in Maternal Diabetes-Induced Heart Defects and the Therapeutic Values of These Cells$602,408
R01 · FY2020 · HL
Characterization of the Cardiac Progenitor Cell Exosomes for Optimal Therapeutics$649,944
R01 · FY2019 · HL · contact PI
The Role of C-Kit Positive Cardiac Progenitors in Maternal Diabetes-Induced Heart Defects and the Therapeutic Values of These Cells$602,408
R01 · FY2019 · HL
The Role of C-Kit Positive Cardiac Progenitors in Maternal Diabetes-Induced Heart Defects and the Therapeutic Values of These Cells$602,408
R01 · FY2018 · HL
Biological Characterization of Cardiac Stem Cells$383,750
R01 · FY2018 · HL · contact PI
The Role of C-Kit Positive Cardiac Progenitors in Maternal Diabetes-Induced Heart Defects and the Therapeutic Values of These Cells$602,408
R01 · FY2017 · HL
Biological Characterization of Cardiac Stem Cells$383,750
R01 · FY2017 · HL · contact PI
Biological Characterization of Cardiac Stem Cells$383,750
R01 · FY2016 · HL · contact PI
Biological Characterization of Cardiac Stem Cells$377,993
R01 · FY2015 · HL · contact PI
Biological Characterization of Cardiac Stem Cells$383,750
R01 · FY2014 · HL · contact PI
Characterization of Cell-Based Therapy for Congenital Heart Patients$129,060
K08 · FY2013 · HL · contact PI
Characterization of Cell-Based Therapy for Congenital Heart Patients$129,060
K08 · FY2012 · HL · contact PI
Characterization of Cell-Based Therapy for Congenital Heart Patients$80,491
K08 · FY2011 · HL · contact PI
Characterization of Cell-Based Therapy for Congenital Heart Patients$48,569
K08 · FY2011 · HL · contact PI
Characterization of Cell-Based Therapy for Congenital Heart Patients$129,060
K08 · FY2010 · HL · contact PI
Characterization of Cell-Based Therapy for Congenital Heart Patients$129,060
K08 · FY2009 · HL · contact PI